Ontology highlight
ABSTRACT:
SUBMITTER: Dompe N
PROVIDER: S-EPMC6005515 | biostudies-other | 2018
REPOSITORIES: biostudies-other
Dompe Nicholas N Klijn Christiaan C Watson Sara A SA Leng Katherine K Port Jenna J Cuellar Trinna T Watanabe Colin C Haley Benjamin B Neve Richard R Evangelista Marie M Stokoe David D
PloS one 20180618 6
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective clinically. We therefore implemented a CRISPR screening approach to identify novel agents to sensitize KRAS mutant NSCLC cells to MEK inhibitor treatment. This approach identified multiple components ...[more]